Meaxin

Imatinib, the active ingredient in Meaxin, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients and is indicated for patients with these malignancies.

GNH USA supplies Meaxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Imatinib is a tyrosine kinase inhibitor used in specific hematologic and solid‑tumor malignancies. - Chronic myeloid leukemia (CML): Reduces proliferation of BCR‑ABL‑positive leukemic cells, leading to hematologic and cytogenetic responses. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Induces remission by inhibiting the BCR‑ABL tyrosine kinase driving uncontrolled lymphoblast growth. - Gastrointestinal stromal tumor (GIST): Suppresses tumor growth by blocking c‑KIT and PDGFR pathways that promote cell survival.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Fatigue: generalized tiredness. - Edema: peripheral swelling, especially of ankles. - Muscle cramps: occasional skeletal muscle discomfort. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: heart failure or decreased left ventricular function. - Severe neutropenia: marked reduction in white blood cells. - Thrombocytopenia: low platelet counts increasing bleeding risk. - Pulmonary hypertension: rare increase in pulmonary arterial pressure.

When prescribing Imatinib, clinicians should consider several precautionary measures to ensure patient safety. - Baseline assessment: Perform complete blood count, liver function tests and renal function before initiating therapy. - Monitoring: Regularly review hematologic parameters and hepatic enzymes during treatment. - Drug interactions: Review concomitant medications for potential CYP3A4 modulators. - Pregnancy and lactation: Avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Cardiovascular risk: Evaluate cardiac function in patients with pre‑existing heart disease. - Store at ambient temperature: Keep tablets below 25°C in the original container, protected from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce Imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase Imatinib levels and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours. - Proton pump inhibitors: can modestly reduce bioavailability; monitor therapeutic response. - Warfarin: potential for altered anticoagulation; check INR more frequently. - Live attenuated vaccines: possible reduced efficacy; consider timing of administration.